6/28/23, 12:22 AM CRHCP Pathway Feedback Search Clinical Topics Home Studies CRHCP CRHCP Disease Hypertension Trial question What is the role of non-physician community healthcare provider-led intensive BP intervention in adults with hypertension? Study design Multi-center Open label RCT Population 33995 patients Inclusion criteria: individuals aged 40 years with an untreated systolic BP 140 mmHg or a diastolic BP 90 mmHg Key exclusion criteria: age < 40 years; pregnancy; life expectancy < 3 years; malignant tumors Interventions N=163 non-physician community healthcare provider-led intervention (initiation and titration of antihypertensive medications to achieve a systolic BP goal < 130 mmHg and diastolic BP goal < 80 mmHg with supervision from primary care physicians) N=163 villages: usual care (villages: no intervention) Primary outcome Incidence of composite of myocardial infarction, stroke, heart failure requiring hospitalization, and cardiovascular disease death during the 36-month follow-up 2.4 % / y 2.4 1.8 % / y 1.62 1.2 % / y 0.6 % / y Significant decrease 0.0 % / y https://web.pathway.md/studies/reccnC0IaMU4AyIfO 1/2 6/28/23, 12:22 AM CRHCP Pathway Non-physician community healthcare provider-led intervention Villages: usual care Significant decrease in the incidence of composite of myocardial infarction, stroke, HF requiring hospitalization, and CVD death during the 36-month follow-up (1.62% / y vs. 2.4% / y; HR 0.67, 95% CI 0.61 to 0.73) Conclusion In individuals aged 40 years with an untreated systolic BP 140 mmHg or a diastolic BP 90 mmHg, non-physician community healthcare provider-led intervention was superior to villages: usual care with respect to the incidence of composite of myocardial infarction, stroke, HF requiring hospitalization, and CVD death during the 36-month follow-up. Reference Jiang He, Nanxiang Ouyang, Xiaofan Guo et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. Lancet. 2023 Mar 18;401(10380):928-938. Open reference URL https://web.pathway.md/studies/reccnC0IaMU4AyIfO 2/2